Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2024-09-25

Clinical Trial Update: Clinical Performance Evaluation of the C2i Test

View source ↗

Summary

The clinical trial NCT05860543 evaluating the C2i Test for muscle-invasive bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Muscle Invasive Bladder Cancer | Status: WITHDRAWN